Illumina, Nvidia team to use AI in foundation models

Illumina and Nvidia Unveil Groundbreaking Collaboration to Decipher Biology and Propel Precision Health

In a monumental announcement, Illumina, a pioneering force in sequencing technologies and software, has revealed its strategic partnership with Nvidia, the leading provider ofcomputer chips and AI solutions. This collaboration aims to revolutionize the analysis of multiomic data, crucial for clinical research, genomics, and drug discovery.

By harnessing Illumina’s sequencing technologies and Nvidia’s computing and AI capabilities, the duo will be establishing biological foundation models that can unravel the complexities of multiomic data with unprecedented precision. The partnership signifies one of several prominent collaborations that Nvidia has engaged in to advance the adoption of AI in the life sciences industry.

For researchers and pharmaceutical companies, this collaboration promises a new era of accessibility in analyzing the human genome. Illumina’s Dragen analysis software and connected analytics platform will be seamlessly integrated with Nvidia’s accelerated computing capabilities. This integration will provide advanced tools for applying generative AI to analyze vast amounts of multiomic data—data that involves a combination of genomics, transcriptomics, and epigenetics.

According to Steve Barnard, Illumina’s chief technology officer, their ability to merge AI with multiomics data is transforming our understanding of disease. The goal is to empower both pharma and biotech companies to unlock their own multiomics data and uncover transformative insights that can significantly improve the success rates in developing lifesaving therapies.

This partnership is part of a broader initiative by Nvidia to advance genetics and healthcare by collaborating with other industry leaders. Alongside Illumina, Nvidia is also partnering with IQVIA, Mayo Clinic, and Arc Institute to leverage its technologies in drug discovery and digital pathology.

As the collaborative efforts between tech giants and medical innovators continue to break new ground, researchers are poised to uncover groundbreaking insights that will pivotal in the quest for precision health. This synergy exemplifies a new era in data-driven medicine, where technology and science converge to drive life-saving advancements.